In the context of MYCN−amplified neuroblastoma, Aurora−A inhibitors (e.g., MLN8054 and MLN8237) disrupt the protective Aurora−A/N−Myc complex, promoting FBXW7−mediated degradation of N−Myc and thus inhibiting tumor growth (291). The gene discussed is MYCN; the disease is neuroblastoma.